DOCSLIB.ORG

Development of the Global Smallpox Eradication Programme, 1958-1966

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Development of the Global Smallpox Eradication Programme, 1958-1966 CHAPTER 9 DEVELOPMENT OF THE GLOBAL SMALLPOX ERADICATION PROGRAMME, 1958-1966 Con tents Page The commitment to global smallpox eradication, 1958- 1959 366 History of the concept of eradication 37 1 Introduction 371 Eradication of animal diseases 372 The first eradication programmes for human diseases- hookworm and yellow fever 373 Aedes aegvptz eradication 377 Eradication of another mosquito vector-Anopheles gambiae 377 Programmes for the eradication of malaria, yaws and other human diseases 379 WHO smallpox control and eradication activities, 1946- 1958 388 Introduction 388 Smallpox eradication in the Region of the Americas 389 An abortive attempt to launch a global smallpox eradication programme, 1953 391 The smallpox eradication programme, 1959-1 966 393 Introduction 393 Status of smallpox, 1959 393 The global eradication programme begins, 1959 394 Budgetary provision for the programme 395 Programme activities, 1959-1 962 395 Proposed provision of support through the WHO regular budget, 1963 399 Voluntary contributions 400 The first WHO Expert Committee on Smallpox, 1964 402 The Seventeenth World Health Assembly, 1964 403 A retrospective view of progress in smallpox eradica- tion, 1959-1964 403 Events leading to the introduction of an intensified global programme, 1965 405 The Eighteenth World Health Assembly, 1965 408 A special budget for smallpox eradication, 1966 409 The Director-General’s report to the Nineteenth World Health Assembly 41 0 365 366 SMALLPOX AND ITS ERADICATION Page The smallpox eradication programme, 1959-1 966 (cont.) The discussions at the Executive Board Uanuary 1966) and at the Nineteenth World Health Assembly (May 1966) 414 Preparations for initiating the Intensified Programme, 1966 416 Summary 41 8 THE COMMITMENT TO GLOBAL complete eradication throughout the world, SMALLPOX ERADICATION, we think that this can be achieved within the 1958-1959 next ten years.” No reference was made to an 8-year-old regional programme for smallpox The decision by the Twelfth World Health eradication in the Americas nor to the Health Assembly, in May 1959, to undertake the Assembly’s earlier discussions on smallpox. global eradication of smallpox marked the The USSR had not participated in those beginning of a programme which, some 18 discussions, however, having withdrawn years later, would witness the last naturally from active participation in WHO from 1948 occurring case. The Health Assembly’s policy, to 1957. which made the global eradication of a disease The new initiative originated with Profes- one of WHO’S goals, was not without prece- sor Zhdanov himself. From 1951, when he dent, a similar decision with regard to malaria had first assumed responsibility for communi- having been taken 4 years before. cable disease control in the USSR, as Chief of The commitment to smallpox eradication the Department of Sanitary and Epidemi- in 1959 represented, for the Health Assembly, ological Services, he had taken an active an abrupt reversal of its views regarding the interest in the concept of disease eradication. disease. The problem of smallpox and its His interest was stimulated, in part, by the control had been the subject of discussions in successful interruption of smallpox trans- the Health Assembly in 1950,1953,1954 and mission throughout the USSR in 1936, and by 1955. An eradication programme had been the elimination of dracunculiasis from the proposed, in fact, by the first Director- Central Asian republics of the USSR follow- General, Dr Brock Chisholm, to the Sixth ing a 10-year campaign that ended in 1932 World Health Assembly in 1953. However, (Isaev, 1956 ;Litvinov, 1970). These successes after 2 years of study and debate, the Eighth led him to initiate a study of infectious World Health Assembly, in May 1955, re- diseases in the Soviet Union for the purpose of jected the concept as unrealistic, and the terse identifying others which might similarly be resolution which was adopted (WHA8.38) eliminated (Zhdanov & Timakov, 1952). By simply urged “that health administrations assigning more resources in the short term to conduct, wherever necessary, campaigns disease elimination, longer-term savings against smallpox as an integral part of their could be anticipated. Smallpox remained a public-health programmes” (World Health problem, however, particularly in the Central Organization, 1973a). Asian republics, because of importations from From 1955 to 1958, the issue of smallpox Afghanistan and Iran, 537 cases being record- eradication lay dormant but, at the Eleventh ed between 1950 and 1957 (Burgasov, 1968). World Health Assembly, Professor Viktor Professor Zhdanov’s report to the Health Zhdanov, Deputy Minister of Health of the Assembly pointed out that the danger which USSR and a delegate to the Health Assembly, endemic countries posed to others caused “the presented a formal, lengthy report which countries which are free from smallpox.. to argued that the problem of smallpox was an make considerable efforts and spend large important one for endemic and non-endemic sums on vaccinating and revaccinating the countries alike, that eradication was theoreti- population in order to provide constant cally feasible and that national programmes strong immunity against this disease”. Small- had demonstrated it to be a practicable pox, as he saw it, would be much easier to possibility (World Health Organization, eradicate than any of the other infectious 1958a). The report concluded: “AS regards its diseases, as indicated by the success of the 9. DEVELOPMENT OF THE GLOBAL PROGRAMME, 1958-1966 367 programme in the USSR. Despite the diverse the world will learn about this disgusting problems presented by a country so large and smallpox disease only from ancient tradi- abundantly populated, transmission had been tions’.’’ The Zhdanov report proposed that stopped by means of a programme of compul- vaccination and revaccination campaigns sory vaccination (Vasil’ev & Vasil’ev, 1982). should be conducted throughout the endemic For other countries to do likewise seemed areas of the world, commencing in 1959. It both logical and feasible and the USSR was recommended that vaccination should be willing to offer its assistance to support such made compulsory and that freeze-dried vac- efforts. In addition to offering 25 million cine should be used. It also suggested that the doses of vaccine to WHO, it informed the programme could be accelerated if the Leices- Director-General at the twenty-third session ter system were introduced as well. This of the Executive Board that it had sent offers system, as noted in the report, was used for of assistance to Burma, Cambodia (later De- outbreak control, mainly in England (see mocratic Kampuchea), Ghana, Guinea, India, Chapter 6), and resembled what eventually Indonesia, Iraq and Pakistan (World Health came to be called surveillanceecontainment Organization, 1959a). activities-namely, “prompt identification The Eleventh World Health Assembly was of the disease, special notification, isola- held in Minneapolis, Minnesota (USA), and, tion, quarantine, disinfection measures”- with this venue in mind, Professor Zhdanov although it included the “eradication of flies” introduced his report with a quotation : “AS as well (Fraser, 1980). early as 1806, the President of the United The draft resolution introduced by the States of America Thomas Jefferson. said in USSR in 1958 for consideration by the Health his letter to Jennet: ‘It is owing to your Assembly differed from the report in suggest- discovery.. that in the future the peoples of ing that eradication in 4-5 years was possible in accordance with the following timetable: (1) preparation of the necessary amount of vaccine in 1958-1960 and the training of vaccinators; (2) vaccination during 1959- 1960 of the populations in which principal endemic foci existed; and (3) completion of eradication in 1961-1 962 by additional vacci- nation and revaccination. Nothing was said of the Leicester system in the resolution. The concept of global eradication was broadly endorsed by virtually all the delegates who spoke, although a number believed that the timetable was too optimistic and some wondered whether there might not be in- superable technical and administrative prob- lems. Accordingly, the resolution was altered to request “the Director-General to study and report to the Executive Board ... on the financial, administrative and technical impli- cations of a programme having as its objective the eradication of smallpox” (see box). Immediately after the Health Assembly, the Executive Board met and formally ac- cepted the gift of freeze-dried vaccine from the USSR, as well as 2 million doses of glycerolated vaccine offered by Cuba. The Plate 9.1. Viktor M. Zhdanov (b. 1914). Academ- Board noted in resolution EB22.Rl2 that the ician and Deputy Minister of Health of the USSR, Director-General would establish a special 1955-1960, proposed to the World Health Assembly account for smallpox eradication, which in 1958 that WHO should undertake the global would “be credited with the value, as reported eradication of smallpox. Many epidemiologists whom he trained while Director of the lvanovsky Institute by the governments concerned, of these gifts served as WHO staff and consultants for the eradi- of vaccine and of any gifts for the same cation of smallpox. purpose which may be accepted by the Board 368 SMALLPOX AND ITS ERADICATION - \ Resolution WHA11.54, adopted at the Eleventh World Health Assembly in 1958 “Noting that smallpox still remains a very
Load more

Recommended publications
  • Malaria History
    This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this site. Copyright 2006, The Johns Hopkins University and David Sullivan. All rights reserved. Use of these materials permitted only in accordance with license rights granted. Materials provided “AS IS”; no representations or warranties provided. User assumes all responsibility for use, and all liability related thereto, and must independently review all materials for accuracy and efficacy. May contain materials owned by others. User is responsible for obtaining permissions for use from third parties as needed. Malariology Overview History, Lifecycle, Epidemiology, Pathology, and Control David Sullivan, MD Malaria History • 2700 BCE: The Nei Ching (Chinese Canon of Medicine) discussed malaria symptoms and the relationship between fevers and enlarged spleens. • 1550 BCE: The Ebers Papyrus mentions fevers, rigors, splenomegaly, and oil from Balantines tree as mosquito repellent. • 6th century BCE: Cuneiform tablets mention deadly malaria-like fevers affecting Mesopotamia. • Hippocrates from studies in Egypt was first to make connection between nearness of stagnant bodies of water and occurrence of fevers in local population. • Romans also associated marshes with fever and pioneered efforts to drain swamps. • Italian: “aria cattiva” = bad air; “mal aria” = bad air. • French: “paludisme” = rooted in swamp. Cure Before Etiology: Mid 17th Century - Three Theories • PC Garnham relates that following: An earthquake caused destruction in Loxa in which many cinchona trees collapsed and fell into small lake or pond and water became very bitter as to be almost undrinkable. Yet an Indian so thirsty with a violent fever quenched his thirst with this cinchona bark contaminated water and was better in a day or two.
    [Show full text]
  • Malaria: Bad for Business Why Investing in Ending Malaria Provides Some of the Highest Economic Returns
    Malaria: Bad for business Why investing in ending malaria provides some of the highest economic returns. Malaria’s burden on the health and wealth of nations While huge progress has been made in recent years, one of the most striking signs of the global impact of the 215 million cases of malaria reported last year is that up to 40% of public health spending goes on the disease in the most heavily affected countries. But malaria reaches far beyond public health, taking its toll on households, local and multinational business profits, and national economic development. Critically, annual economic growth in countries with high malaria transmission has historically been lower than in countries without malaria. In some African countries, malaria reduces GDP growth up to an estimated 1.3%. Malaria costs productivity. Adults are forced to be absent from work, children miss school, and households spend disproportionately on health when they can least afford it. But it need not be this way. With developing countries, donors and private sector firms beginning to take real action, we can be the generation that ends malaria for good and boosts prosperity for all. The economic growth penalty Malaria’s impact on national economies Malaria and poverty occupy common ground. Where the burden of malaria is highest, economic prosperity is lowest. We know that poverty can promote malaria transmission, and that malaria causes poverty by blocking economic growth. Research shows that malaria can strain national economics, having a deleterious impact on some nations’ GDP by as much as an estimated 5 - 6%. It keeps households in poverty, discourages domestic and foreign investment and tourism, affects land use patterns, and reduces productivity through lost work days and diminished job performance.
    [Show full text]
  • COVID-19 Surveillance Seminar - July 6, 2020
    COVID-19 Surveillance Seminar - July 6, 2020 Leveraging Systems for COVID-19 Surveillance Integrated Disease Surveillance and Response (IDSR), Malaria, and Polio Michelle Sloan, Division of Global Health Protection John Painter, Division of Parasitic Diseases and Malaria Wilbrod Mwanje, African Field Epidemiology Network (AFENET), Uganda cdc.gov coronavirus www.cdc.go /corona irus/2019-nco /global-co id-19 Integrated Disease Surveillance and Response (IDSR) . Integrates common sur eillance acti ities across diseases – Identify, Report, Analyze and Interpret, In estigate and Confirm, Prepare, Respond, Communicate, E aluate – Acti ities linked across community, district, and national le els of the health system . Reporting on country identified priority diseases (e.g. case based, aggregate) . Standardized data collection tools and data reporting to district le el . Thresholds defined for public health response . Impro ed data use through routine data analysis Incorporating COVID-19 into IDSR . Include COVID-19 on country priority disease list . De elop COVID-19 reporting tools – Indi idual case report, aggregate reporting form, contact tracing form . Train sur eillance focal points – Case identification using standard case definition – Immediate reporting of suspect cases . Case-based reporting of cases and deaths (aggregate if resources constrained) . Initiate response strategies based on threshold, for example – In estigation and contact tracing for each indi idual case – Population le el inter entions for clusters and outbreaks Leveraging Other IDSR Data . Monitor existing disease sur eillance for signals – Influenza – Malaria – Other fe er producing diseases . Indicators to analyze – Case and death counts – Trends – Geographical spread – Completeness – Timeliness Leveraging Other Disease Surveillance Strategies . Identify potential signals o erall or by region where there might be missed COVID-19 cases – Malaria sur eillance .
    [Show full text]
  • Strengthening Malaria Surveillance for Data- Driven Decision Making in Mozambique
    MALARIA CONSORTIUM PROJECT BRIEF Strengthening malaria surveillance for data- driven decision making in Mozambique Accelerating efforts to reduce the malaria burden by improving data quality and use across all transmission strata Background Country Mozambique Although Mozambique has made some progress in scaling up malaria control activities and aligning its malaria elimination efforts with neighbouring countries Donor Bill & Melinda Gates Foundation in southern Africa over the last decade, it remains the fourth largest contributor of malaria cases globally.[1] Length of project May 2019 – May 2022 To accelerate efforts to reduce the malaria burden, Mozambique urgently needs a fit-for-purpose surveillance system to provide the necessary intelligence to identify Partners bottlenecks in malaria control and elimination activities, target interventions more Clinton Health Access Initiative efficiently and respond when the impact of National Malaria Control Programme Goodbye Malaria/LSDI2 activities is jeopardised. Manhica Health Research Centre Ministry of Health A malaria surveillance system is considered functional and responsive when it World Health Organization can produce evidence-based information from quality data that is routinely used Collaborator for planning and decision making. The 2018 national malaria surveillance system U.S. President’s Malaria Initiative assessment identified the following main obstacles: • poor malaria data quality (DQ) and data use (DU) • lack of an integrated malaria information storage system (iMISS) •
    [Show full text]
  • Malaria and COVID-19: Common and Different Findings
    Tropical Medicine and Infectious Disease Viewpoint Malaria and COVID-19: Common and Different Findings Francesco Di Gennaro 1 , Claudia Marotta 1,*, Pietro Locantore 2, Damiano Pizzol 3 and Giovanni Putoto 1 1 Operational Research Unit, Doctors with Africa CUAMM, 35121 Padova, Italy; [email protected] (F.D.G.); [email protected] (G.P.) 2 Institute of Endocrinology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy; [email protected] 3 Italian Agency for Development Cooperation, Khartoum 79371, Sudan; [email protected] * Correspondence: [email protected] or [email protected] Received: 31 July 2020; Accepted: 3 September 2020; Published: 6 September 2020 Abstract: Malaria and COVID-19 may have similar aspects and seem to have a strong potential for mutual influence. They have already caused millions of deaths, and the regions where malaria is endemic are at risk of further suffering from the consequences of COVID-19 due to mutual side effects, such as less access to treatment for patients with malaria due to the fear of access to healthcare centers leading to diagnostic delays and worse outcomes. Moreover, the similar and generic symptoms make it harder to achieve an immediate diagnosis. Healthcare systems and professionals will face a great challenge in the case of a COVID-19 and malaria syndemic. Here, we present an overview of common and different findings for both diseases with possible mutual influences of one on the other, especially in countries with limited resources. Keywords: malaria; SARS-CoV-2; COVID-19; preparedness; Africa; emergency; pandemic 1. Background On 11 March 2020, the WHO declared the outbreak of SARS-CoV-2 to be a pandemic infection.
    [Show full text]
  • The Columbian Exchange: a History of Disease, Food, and Ideas
    Journal of Economic Perspectives—Volume 24, Number 2—Spring 2010—Pages 163–188 The Columbian Exchange: A History of Disease, Food, and Ideas Nathan Nunn and Nancy Qian hhee CColumbianolumbian ExchangeExchange refersrefers toto thethe exchangeexchange ofof diseases,diseases, ideas,ideas, foodfood ccrops,rops, aandnd populationspopulations betweenbetween thethe NewNew WorldWorld andand thethe OldOld WWorldorld T ffollowingollowing thethe voyagevoyage ttoo tthehe AAmericasmericas bbyy ChristoChristo ppherher CColumbusolumbus inin 1492.1492. TThehe OldOld WWorld—byorld—by wwhichhich wwee mmeanean nnotot jjustust EEurope,urope, bbutut tthehe eentirentire EEasternastern HHemisphere—gainedemisphere—gained fromfrom tthehe CColumbianolumbian EExchangexchange iinn a nnumberumber ooff wways.ays. DDiscov-iscov- eeriesries ooff nnewew ssuppliesupplies ofof metalsmetals areare perhapsperhaps thethe bestbest kknown.nown. BButut thethe OldOld WWorldorld aalsolso ggainedained newnew staplestaple ccrops,rops, ssuchuch asas potatoes,potatoes, sweetsweet potatoes,potatoes, maize,maize, andand cassava.cassava. LessLess ccalorie-intensivealorie-intensive ffoods,oods, suchsuch asas tomatoes,tomatoes, chilichili peppers,peppers, cacao,cacao, peanuts,peanuts, andand pineap-pineap- pplesles wwereere aalsolso iintroduced,ntroduced, andand areare nownow culinaryculinary centerpiecescenterpieces inin manymany OldOld WorldWorld ccountries,ountries, namelynamely IItaly,taly, GGreece,reece, andand otherother MediterraneanMediterranean countriescountries (tomatoes),(tomatoes),
    [Show full text]
  • Diseases of Poverty and the 10/90 Gap Diseases of Poverty and the 10/90 Gap Diseases of Poverty and the 10/90 Gap
    Diseases of poverty and the 10/90 gap Diseases of poverty and the 10/90 Gap Diseases of poverty and the 10/90 Gap Written by Philip Stevens, Director of Health Projects, International Policy Network November 2004 International Policy Network Third Floor, Bedford Chambers The Piazza London WC2E 8HA UK t : +4420 7836 0750 f: +4420 7836 0756 e: [email protected] w : www.policynetwork.net © International Policy Network 2004 Designed and typeset in Latin 725 by MacGuru Ltd [email protected] Cover design by Sarah Hyndman Printed in Great Britain by Hanway Print Centre 102–106 Essex Road Islington N1 8LU All rights reserved. Without limiting the rights under copyright reserved above, no part of this publication may be reproduced, stored or introduced into a retrieval system, or transmitted, in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of both the copyright owner and the publisher of this book. Diseases of poverty and the 10/90 Gap Introduction: What is the 10/90 Gap? Figure 1 Number of daily deaths from diseases7 Activists claim that only 10 per cent of global health research is devoted to conditions that account for 90 Respiratory 10,814 per cent of the global disease burden – the so-called infections 1 ‘10/90 Gap’. They argue that virtually all diseases HIV/ 7,852 AIDS prevalent in low income countries are ‘neglected’ Diarrhoeal 5,482 and that the pharmaceutical industry has invested diseases almost nothing in research and development (R&D) Tuberculosis 4,504 for these diseases.
    [Show full text]
  • UGANDA Who We Are
    UGANDA WHO WE ARE The principal aim of The organisation works to monitoring and evaluation Malaria Consortium is the improve not only the health and operational research. of the individual, but also the Since then, the Malaria Consortium prevention and treatment of capacity of national health disease, particularly but not Uganda programme has expanded systems and communities, its focus to include tuberculosis, exclusively malaria, among which contributes towards pneumonia, diarrhoea and the poorest and most at risk. poverty relief and improved neglected tropical diseases. Malaria Consortium works economic prosperity. Cross cutting aspects such as in a variety of settings Malaria Consortium started health system strengthening, accross Africa and Asia, its Uganda programme in 2003 private sector support, maternal to provide technical assistance and child health are also becoming using innovative strategies to the Ministry of Health (MoH) important priorities. Contributing and approaches. and partners in malaria strategy quality work to the evidence base and policy development, for disease control interventions implementation support, remains a critical focus. Uganda has the third highest malaria burden in Africa, with the disease being the cause of 50 percent of out-patient cases and 14 percent of in-patient deaths. Malaria Consortium is registered in the UK as Charity No. 1099776. WHat WE DO The Uganda programme DISEASE PREVENTION CASE managEMENT has reached almost all of Preventive activities aim to & DIagnOSTICS the more than one hundred rapidly reduce the incidence Technical assistance to the MoH districts in Uganda. of malaria and other diseases. focuses on policies and guidelines, Activities include the distribution training, supply chain management of millions of long lasting to distribute drugs and supplies, insecticidal nets through mass and diagnostic support including campaigns and routinely through the introduction of external quality health facilities, the promotion of assurance systems.
    [Show full text]
  • The Impact of COVID-19 on HIV, TB and Malaria Services and Systems for Health | 2 METHODOLOGY
    THE IMPACT OF COVID-19 ON HIV, TB AND MALARIA SERVICES AND SYSTEMS FOR HEALTH: A SNAPSHOT FROM 502 HEALTH FACILITIES ACROSS AFRICA AND ASIA © UNICEF / Singh INTRODUCTION In 2020, the COVID-19 pandemic impacted the world beyond imagination. To date, it has infected more than 135 million people, killed over 2.9 million people, and is projected to plunge up to 115 million people into extreme poverty.1 As countries have gone into lockdown, gender-based violence has increased, unemployment has soared, and access to health care for the poorest and most vulnerable has been cut. COVID-19 has made people less likely to seek health care because they are afraid of getting infected with the virus. Fear and uncertainty surrounding COVID-19 have also increased stigma and discrimination. As frontline workers without enough access to personal protective equipment (PPE) risk their lives to treat patients, the virus pushes already fragile health systems to the brink. To make matters worse, new mutations of the virus have the development and equitable distribution of tests, emerged. The new variants threaten the effectiveness treatments and vaccines – and the strengthening of the existing array of COVID-19 tools, including the of health systems – that the world needs to defeat progress made with treatments and the development COVID-19. of vaccines, underscoring the urgent need to contain COVID-19 in all countries. The pandemic is creating a The fight against COVID-19 is at a critical juncture, perfect storm of economic, health and social crises and and we must act urgently to mitigate the pandemic’s threatens to reverse the extraordinary gains made by disruption to systems for health and to the crucial the Global Fund partnership in the fight against HIV, health services they sustain.
    [Show full text]
  • Plasmodium Falciparum Full Life Cycle and Plasmodium Ovale Liver Stages in Humanized Mice
    ARTICLE Received 12 Nov 2014 | Accepted 29 May 2015 | Published 24 Jul 2015 DOI: 10.1038/ncomms8690 OPEN Plasmodium falciparum full life cycle and Plasmodium ovale liver stages in humanized mice Vale´rie Soulard1,2,3, Henriette Bosson-Vanga1,2,3,4,*, Audrey Lorthiois1,2,3,*,w, Cle´mentine Roucher1,2,3, Jean- Franc¸ois Franetich1,2,3, Gigliola Zanghi1,2,3, Mallaury Bordessoulles1,2,3, Maurel Tefit1,2,3, Marc Thellier5, Serban Morosan6, Gilles Le Naour7,Fre´de´rique Capron7, Hiroshi Suemizu8, Georges Snounou1,2,3, Alicia Moreno-Sabater1,2,3,* & Dominique Mazier1,2,3,5,* Experimental studies of Plasmodium parasites that infect humans are restricted by their host specificity. Humanized mice offer a means to overcome this and further provide the opportunity to observe the parasites in vivo. Here we improve on previous protocols to achieve efficient double engraftment of TK-NOG mice by human primary hepatocytes and red blood cells. Thus, we obtain the complete hepatic development of P. falciparum, the transition to the erythrocytic stages, their subsequent multiplication, and the appearance of mature gametocytes over an extended period of observation. Furthermore, using sporozoites derived from two P. ovale-infected patients, we show that human hepatocytes engrafted in TK-NOG mice sustain maturation of the liver stages, and the presence of late-developing schizonts indicate the eventual activation of quiescent parasites. Thus, TK-NOG mice are highly suited for in vivo observations on the Plasmodium species of humans. 1 Sorbonne Universite´s, UPMC Univ Paris 06, CR7, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l’hoˆpital, F-75013 Paris, France.
    [Show full text]
  • Plasmodium Asexual Growth and Sexual Development in the Haematopoietic Niche of the Host
    REVIEWS Plasmodium asexual growth and sexual development in the haematopoietic niche of the host Kannan Venugopal 1, Franziska Hentzschel1, Gediminas Valkiūnas2 and Matthias Marti 1* Abstract | Plasmodium spp. parasites are the causative agents of malaria in humans and animals, and they are exceptionally diverse in their morphology and life cycles. They grow and develop in a wide range of host environments, both within blood- feeding mosquitoes, their definitive hosts, and in vertebrates, which are intermediate hosts. This diversity is testament to their exceptional adaptability and poses a major challenge for developing effective strategies to reduce the disease burden and transmission. Following one asexual amplification cycle in the liver, parasites reach high burdens by rounds of asexual replication within red blood cells. A few of these blood- stage parasites make a developmental switch into the sexual stage (or gametocyte), which is essential for transmission. The bone marrow, in particular the haematopoietic niche (in rodents, also the spleen), is a major site of parasite growth and sexual development. This Review focuses on our current understanding of blood-stage parasite development and vascular and tissue sequestration, which is responsible for disease symptoms and complications, and when involving the bone marrow, provides a niche for asexual replication and gametocyte development. Understanding these processes provides an opportunity for novel therapies and interventions. Gametogenesis Malaria is one of the major life- threatening infectious Malaria parasites have a complex life cycle marked Maturation of male and female diseases in humans and is particularly prevalent in trop- by successive rounds of asexual replication across gametes. ical and subtropical low- income regions of the world.
    [Show full text]
  • Malaria Consortium
    Malaria Consortium 2003-2013: a decade in communicable disease control and child health Contents 1 Chair’s foreword 2 Our birth and growth 6 Malaria Consortium, 2003-2013 8 Our evolution at country level 14 Disease control: malaria and neglected tropical diseases 22 Linking the community to health systems 30 Moving to elimination 38 Going forward Thank you The last 10 years for Malaria Consortium have been made possible thanks to the unwavering support of our donors, partners and collaborators from across the world. Collaboration and cooperation with others has been the cornerstone of all our achievements in the fight against malaria and other communicable childhood and neglected tropical diseases. It is thanks to these partnerships that we are able to provide some of the world’s most vulnerable people with better health care and offer them a chance for a future free from the burden of diseases which are treatable and preventable. t A key focus of Malaria Consortium has been effective diagnosis of malaria which helps save millions of lives Tadej Znidarcic Tadej Growing through innovation and partnership Malaria Consortium was founded by a small team of people with a vision – to build the capacity of malaria-endemic countries worldwide to deal with a common and treatable disease that was devastating the lives of poor and vulnerable communities. Over the course of a decade of innovation and Whilst the organisation has grown significantly, our strong partnerships, this vision has grown from focus on the national and grassroots level has enabled focusing solely on malaria control and prevention, us to remain an effective on-the-ground partner, which to include integrated approaches to improving child has meant that in all that we have done, we have health and neglected tropical diseases.
    [Show full text]